Search

Your search keyword '"Infection -- Drug therapy"' showing total 64 results
Start Over Descriptor "Infection -- Drug therapy" Journal globenewswire
64 results on '"Infection -- Drug therapy"'

1. BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Subjects
Communicable diseases -- Drug therapy, Cystic fibrosis -- Drug therapy, Infection -- Drug therapy, Microbiology -- Health aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX' or the 'Company'), a clinical-stage company advancing novel natural and engineered phage [...]

Published
2024

2. Basilea announces US FDA approval of antibiotic ZEVTERA(R) (ceftobiprole medocaril) for three indications

Subjects
United States. Food and Drug Administration, Staphylococcus aureus -- Forecasts and trends -- Health aspects, Endocarditis -- Drug therapy, Infection -- Drug therapy, Staphylococcus aureus infections -- Drug therapy, Children -- Health aspects, Methicillin -- Forecasts and trends -- Health aspects, Drug approval -- Health aspects -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]

Published
2024

3. Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection

Subjects
Antiviral agents -- Health aspects, Infection -- Drug therapy, Virus diseases -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European Medicines Agency (EMA) [...]

Published
2024

4. BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Subjects
United States. Food and Drug Administration, Cystic fibrosis -- Drug therapy, Orphan drugs -- Health aspects, Infection -- Drug therapy, Pseudomonas aeruginosa -- Health aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX'), a clinical-stage company advancing novel natural and engineered phage therapies that target [...]

Published
2024

5. Osteal Therapeutics' VT-X7 Receives FDA's Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial

Subjects
United States. Food and Drug Administration, Infection -- Drug therapy, Clinical trials -- Health aspects, Banking, finance and accounting industries, Business
Abstract

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for VT-X7, Osteal Therapeutics' ('Osteal's') investigational drug therapy for periprosthetic joint infection [...]

Published
2023

6. CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

Subjects
United States. Food and Drug Administration, Catheterization, Infection -- Drug therapy, Hemodialysis, Banking, finance and accounting industries, Business
Abstract

- First and only FDA-approved antimicrobial catheter lock solution in the U.S. - Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. [...]

Published
2023

7. Anti-Infective Drugs Market to Hit USD 177.9 billion by 2031 | Transparency Market Research Inc

Subjects
Tetracycline -- Market research, Drugs -- Market research, Marketing research -- Forecasts and trends -- Health aspects, Infection -- Drug therapy, Tetracyclines -- Market research, Disease susceptibility -- Drug therapy, Marketing research, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

Wilmington, Delaware, United States, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global anti-infective drugs market is projected to flourish https://www.globenewswire.com/Tracker?data=oQaTmMtzQxeTUf_GzLBSquE0I79TNC4IzRxJk32eb1NmLN_OKWmitzvFW-VPnXAJ5zZcXH8_D7_UMiDYqBzyCB78wWGCfXorLl7IyLZMpzSPkbYYRPPlZSrY3zeNxI4jUUt9ewZ4Cir-Jd3t2785YR43tEoUMe94YDcR0GSkaGI= from 2023 to 2031. As [...]

Published
2023

8. Malaria Treatment Market Size to Hit 28.5% CAGR, Globally, by 2030 - Exclusive Report by The Insight Partners

Subjects
Insight Partners, Drugs -- Prescribing, Parasitic diseases -- Drug therapy, Infection -- Drug therapy, Malaria -- Drug therapy, Venture capital companies -- Health aspects, Banking, finance and accounting industries, Business
Abstract

Pune, India, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Malaria is a serious infection spread by an infected mosquito. The infection is very common in certain parts of the world, such [...]

Published
2023

9. Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA(R) TRIPLE PAK(R) (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA(R) DUAL PAK(R) (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Subjects
United States. Food and Drug Administration, Antiulcer drugs -- Health aspects, Helicobacter infections -- Drug therapy, Amoxicillin -- Health aspects, Helicobacter pylori -- Health aspects, Rilpivirine -- Health aspects, Clarithromycin -- Health aspects, Infection -- Drug therapy, Drug approval -- Health aspects, Adults -- Health aspects, Banking, finance and accounting industries, Business, Voquezna Triple (Medication) -- Health aspects, Voquezna Dual (Medication) -- Health aspects
Abstract

Planning for a December 2023 U.S. launch for H. pylori , together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE [...]

Published
2023

10. 60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Subjects
United States. National Institute of Allergy and Infectious Diseases, Microorganisms -- Health aspects, Infection -- Drug therapy, Tafenoquine -- Health aspects, Antifungal agents -- Health aspects, Banking, finance and accounting industries, Business
Abstract

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated [...]

Published
2023

11. Dermatophytic Onychomycosis Treatment Market Size to Reach USD 8.5 Billion by 2032 at 7.90% CAGR - Report by Market Research Future (MRFR)

Subjects
Onychomycosis -- Drug therapy, Marketing research -- Forecasts and trends, Infection -- Drug therapy, Antifungal agents -- Market research, Marketing research, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

New York, USA, July 11, 2023 (GLOBE NEWSWIRE) -- Dermatophytic Onychomycosis Treatment Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), 'https://www.globenewswire.com/Tracker?data=65xfigmytSlfk7UEkwd7Rt-7zM4HNUzHkpYObU7f8Efm4XYg9RfE6B6kaTpDIrpG5N9dDnzHC-gA4Kx9Gvr3p6jfB9pWDPum8THa7oNLdm0iPUjXhKvAa5v6v8di_h9gIQ6fVkeXiTnZ4QW27dukmFhY8NoWjsphxhF5Lqtlbx72GQ9qh06qLcV3U_iZCe5GYyXhJkqlnfyN2izgEEs8tzihQFU6GQ09Uz9XBP7UJkg= Information By Product Type, [...]

Published
2023

12. Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Hepatitis C virus -- Health aspects, Infection -- Drug therapy, Virus diseases -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ('Atea'), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral [...]

Published
2023

13. Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections

Subjects
Beta lactamases -- Health aspects, Drug resistance in microorganisms -- Drug therapy, Bacterial infections -- Drug therapy, Infection -- Drug therapy, Clinical trials -- Health aspects, Banking, finance and accounting industries, Business
Abstract

MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due t o its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii Labege , France - [...]

Published
2023

14. The Global Antifungal Drugs Market to Surpass USD 19 Billion Mark by 2027 | DelveInsight

Subjects
Nonprescription drugs -- Forecasts and trends, Infection -- Drug therapy, Posaconazole -- Forecasts and trends, Caspofungin -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

New York, USA, March 15, 2023 (GLOBE NEWSWIRE) -- The Global Antifungal Drugs Market to Surpass USD 19 Billion Mark by 2027 | DelveInsight The antifungal drugs market is expanding [...]

Published
2023

15. Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818's (ITK Inhibitor) Potential to Block HIV Latency Reversal

Subjects
HIV (Viruses) -- Drug therapy, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Highly active antiretroviral therapy -- Health aspects, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and Opportunistic Infections [...]

Published
2023

16. Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Subjects
Oncology, Experimental -- Health aspects -- Laws, regulations and rules, Infection control -- Health aspects -- Laws, regulations and rules, Mortality -- Spain, Drug resistance in microorganisms -- Drug therapy, Biotechnology -- Laws, regulations and rules -- Health aspects, Biotechnology industry -- Product development, Infection -- Drug therapy, Lung cancer -- Drug therapy, Cancer -- Research, Government regulation, Banking, finance and accounting industries, Business
Abstract

-- First 'living medicine' to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital settings - -- Data demonstrate treatment reduced lung infection and [...]

Published
2023

17. Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Subjects
United States. Food and Drug Administration, Molluscum contagiosum -- Drug therapy, Infection -- Drug therapy, Drug approval -- Health aspects, Skin -- Health aspects, Banking, finance and accounting industries, Business
Abstract

- Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines - - Molluscum contagiosum is a viral skin [...]

Published
2023

18. BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Communicable diseases -- Drug therapy, Infection -- Drug therapy, Herpes -- Drug therapy, RNA -- Health aspects, Clinical trials -- Health aspects, Vaccines -- Product development, Herpesvirus diseases -- Drug therapy, Banking, finance and accounting industries, Business, World Health Organization, University of Pennsylvania
Abstract

First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech's infectious disease mRNA vaccine collaboration with the [...]

Published
2022

19. F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Subjects
United States. Food and Drug Administration, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

Application submitted under priority review with PDUFA target action date set for June 17, 2023 NDA submission is based on positive data from ongoing Phase 2b open-label study of oral [...]

Published
2022

20. Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women's Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Subjects
Women -- Health aspects, Infection -- Drug therapy, Body mass index -- Health aspects, Banking, finance and accounting industries, Business
Abstract

Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001). In the pooled analysis, patients receiving ibrexafungerp experienced significantly higher [...]

Published
2022

21. When Antibiotics Fail, Lifestyle Healing Institute Provides Holistic Chronic Lyme Treatment

Subjects
Bacterial infections -- Drug therapy, Infection -- Drug therapy, Disease transmission -- Health aspects, Mediation -- Health aspects, Antibiotics -- Health aspects, Lyme disease -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

NAPLES, Fla., Sep 19, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END Spring and summer are when people are most likely to encounter ticks and to contract Lyme disease from [...]

Published
2022

22. ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

Subjects
Drug resistance in microorganisms -- Drug therapy, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

YONKERS, Apr 18, 2022 (GLOBE NEWSWIRE via COMTEX) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including [...]

Published
2022

23. Photodisinfection technology could be a game-changer in fight against antimicrobial resistance

Subjects
Technology -- Health aspects, Drug resistance in microorganisms -- Drug therapy, Bacterial infections -- Drug therapy, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

Vancouver, Canada, Jan 21, 2022 (GLOBE NEWSWIRE via COMTEX) -- -- Ondine Biomedical's photodisinfection technology is one of the only new technologies available to economically combat drug-resistant infections. -- Ondine [...]

Published
2022

24. Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection

Subjects
Gilead Sciences Inc. -- Product development, Biological products industry -- Product development, Biotechnology -- Health aspects, Infection -- Drug therapy, Hepatitis B -- Drug therapy, Clinical trials -- Health aspects, Hepatitis B virus -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO, Dec 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV - Vir Biotechnology, [...]

Published
2021

25. SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Subjects
United States. Food and Drug Administration, Communicable diseases -- Drug therapy, Drug resistance -- Drug therapy, Infection -- Drug therapy, Clinical trials -- Health aspects, Body mass index -- Health aspects, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Oct 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Post hoc analysis found ibrexafungerp demonstrated consistent efficacy in important patient sub-populations, characterized by race/ethnicity and body mass [...]

Published
2021

26. SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

Subjects
United States. Food and Drug Administration, Drug resistance in microorganisms -- Drug therapy, Infection -- Drug therapy, Antifungal agents -- Health aspects, Clinical trials -- Health aspects, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Oct 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]

Published
2021

27. SCYNEXIS Announces U.S. Availability of BREXAFEMME(R) (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

Subjects
United States. Food and Drug Administration, Drugs -- Prescribing, Drug resistance -- Drug therapy, Infection -- Drug therapy, Antifungal agents -- Health aspects, Drug approval -- Health aspects, Candidiasis -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Sep 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, [...]

Published
2021

28. Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA(R) (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

Subjects
United States. Food and Drug Administration, Paratek Pharmaceuticals Inc., Lung diseases -- Drug therapy, Orphan drugs -- Health aspects, Infection -- Drug therapy, Methicillin -- Health aspects, Pharmaceutical industry -- Health aspects, Banking, finance and accounting industries, Business, Nuzyra (Medication) -- Health aspects
Abstract

BOSTON, Aug 18, 2021 (GLOBE NEWSWIRE via COMTEX) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening [...]

Published
2021

29. SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

Subjects
United States. Food and Drug Administration, Drug resistance in microorganisms -- Drug therapy, Infection -- Drug therapy, Body mass index, Candidiasis -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, Jul 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- The pooled data from two Phase 3 studies (VANISH-303 and VANISH-306) of one-day oral ibrexafungerp reflect a population that [...]

Published
2021

30. Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Subjects
Biotechnology -- Health aspects, Infection -- Drug therapy, Hepatitis B -- Drug therapy, Clinical trials -- Health aspects, Hepatitis B virus -- Drug therapy, Monoclonal antibodies -- Health aspects, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO, July 15, Jul 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 [...]

Published
2021

31. Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

Subjects
Communicable diseases -- Drug therapy, Infection -- Drug therapy, Antibacterial agents -- Product development, Clinical trials -- Health aspects, Banking, finance and accounting industries, Business
Abstract

Cambridge, MA, Jul 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit' or the 'Company') is today displaying three preeminent ePosters at the prestigious 31st European [...]

Published
2021

32. SCYNEXIS Announces FDA Approval of BREXAFEMME(R) (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Subjects
United States. Food and Drug Administration, Infection -- Drug therapy, Antifungal agents -- Health aspects, Drug approval -- Health aspects, Candidiasis -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, Jun 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today [...]

Published
2021

33. Cytomegalovirus Infection Emerging Drugs to Boost Treatment Prospects

Subjects
Drugs -- Health aspects, Cytomegalovirus infections -- Drug therapy, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

Los Angeles, USA , May 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- Cytomegalovirus Infection Emerging Drugs to Boost Treatment Prospects A plethora of companies is evaluating their drug candidates resulting [...]

Published
2021

34. ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit

Subjects
Drug resistance in microorganisms -- Drug therapy, Infection -- Drug therapy, Antibiotics, Banking, finance and accounting industries, Business
Abstract

YONKERS, Apr 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including [...]

Published
2021

35. Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection

Subjects
Arbutus Biopharma Corp. -- Product development, Infection -- Drug therapy, Hepatitis B -- Drug therapy, Clinical trials -- Health aspects, Coronaviruses -- Health aspects, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business
Abstract

WARMINSTER, Mar 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B [...]

Published
2021

36. Recce Pharmaceuticals Announces The Pew Charitable Trusts' Addition of Recce's Lead Compound RECCE(R) 327 to List of Antibiotic Treatments in Clinical Development

Subjects
Bacterial infections -- Drug therapy, Infection -- Drug therapy, Charitable trusts, Antibiotics, Banking, finance and accounting industries, Business, Pew Charitable Trusts
Abstract

SYDNEY Australia, March 15, Mar 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- Highlights: Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), is pleased to announce its lead compound RECCE 327 (R327) has been [...]

Published
2021

37. Sepsis Management Analysis, 2020 Report - Treatments Focused Towards Antibiotics, Inhibitors, Antibodies, Peptides, Recombinant Proteins, Antibacterial, Antifungal, Antivirals, Vaccines, & Probiotics

Subjects
Management science -- Analysis, Infection -- Drug therapy, Antibacterial agents -- Analysis, Antifungal agents -- Analysis, Vaccines -- Analysis, Recombinant proteins -- Analysis, Peptides -- Analysis, Probiotics -- Analysis, Company business management, Banking, finance and accounting industries, Business
Abstract

Dublin, Jan 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- The 'Analysing Sepsis Management Part II: Treatments' report has been added to ResearchAndMarkets.com's offering. This research study begins by highlighting the [...]

Published
2021

38. Global Hospital Infection Therapeutics Market to 2025 by Drug Type, Indication, Value Chain Analysis, Price Analysis

Subjects
Hospitals -- Forecasts and trends -- Health aspects, Antiviral agents -- Health aspects -- Forecasts and trends, Infection -- Drug therapy, Caspofungin -- Health aspects -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

Dublin, Dec 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025' report has been added to ResearchAndMarkets.com's [...]

Published
2020

39. SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections

Subjects
United States. Food and Drug Administration, Drug resistance in microorganisms -- Drug therapy, Infection -- Drug therapy, Antifungal agents -- Health aspects, Drug approval -- Health aspects, Candidiasis -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Dec 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]

Published
2020

40. RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

Subjects
United States. Food and Drug Administration -- Officials and employees, Rifabutin -- Planning, Orphan drugs -- Planning, Medical research, Infection -- Drug therapy, Naloxegol, Biological products industry -- Officials and employees, Company business planning, Banking, finance and accounting industries, Business
Abstract

TEL AVIV, Israel and RALEIGH, N.C., Oct 14, 2020 (GLOBE NEWSWIRE via COMTEX) -- RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming [...]

Published
2020

41. SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection

Subjects
United States. Food and Drug Administration, Mycoses -- Drug therapy, Microbial drug resistance -- Drug therapy, Antifungal agents, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Oct 14, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- NDA submission is supported by positive data from two Phase 3 studies (VANISH Program) in women with vulvovaginal [...]

Published
2020

42. SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference

Subjects
Mycoses -- Drug therapy, Women's health -- Health aspects, Microbial drug resistance -- Drug therapy, Antifungal agents -- Health aspects, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Oct 12, 2020 (GLOBE NEWSWIRE via COMTEX) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]

Published
2020

43. PolyPid Granted Fast Track Designation from FDA for D-PLEXa?a??a?? for Prevention of Surgical Site Infections in Abdominal Surgery

Subjects
United States. Food and Drug Administration, Surgery -- Health aspects, Infection -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

PETAH TIKVA, Israel, Aug 03, 2020 (GLOBE NEWSWIRE via COMTEX) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics [...]

Published
2020

44. Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection

Subjects
United States. Food and Drug Administration, Hepatitis B virus -- Drug therapy, Biotechnology industries -- Health aspects, Infection -- Drug therapy, Hepatitis B -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Jul 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases [...]

Published
2020

45. CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin(R)

Subjects
Catheterization -- Health aspects, Microbial drug resistance -- Drug therapy, Infection -- Drug therapy, Backup software, Drug resistance, Diseases, Banking, finance and accounting industries, Business
Abstract

BERKELEY HEIGHTS, May 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment [...]

Published
2020

46. RedHill Biopharma Announces Preferred Position for Talicia(R) on Express Scripts National Preferred Formulary Effective March 13, 2020

Subjects
United States. Food and Drug Administration -- Officials and employees, Express Scripts Inc. -- Officials and employees, Rifabutin, Microbial drug resistance -- Drug therapy, Biological products industry -- Officials and employees, Rilpivirine, Health care industry -- Officials and employees, Amoxicillin, Delavirdine, Infection -- Drug therapy, Naloxegol, Gastrointestinal diseases -- Drug therapy, Omeprazole, Drug approval, Health maintenance organizations -- Officials and employees, Helicobacter infections -- Drug therapy, Antibacterial agents, Diseases, Rifamycins, Antiulcer agents, Clarithromycin, Penicillins, Helicobacter pylori, Health care industry, Banking, finance and accounting industries, Business
Abstract

TEL-AVIV, Israel and RALEIGH, Mar 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- RedHill recently launched Talicia in the U.S., calling on gastroenterologists, primary care physicians and other healthcare providers --- [...]

Published
2020

47. RedHill Biopharma Announces U.S. Commercial Launch of Talicia(R) for H. pylori Infection

Subjects
United States. Food and Drug Administration -- Officials and employees, Biological products industry -- Officials and employees, Medical research, Rilpivirine, Rifabutin, Infection -- Drug therapy, Drug approval, Antiulcer drugs, Medicine, Experimental, Delavirdine, Helicobacter infections -- Drug therapy, Drug resistance in microorganisms -- Drug therapy, Helicobacter pylori, Stomach cancer -- Drug therapy, Banking, finance and accounting industries, Business, Talicia (Medication)
Abstract

TEL-AVIV, Israel and RALEIGH, Mar 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Talicia is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a [...]

Published
2020

48. RedHill Biopharma Announces FDA Approval of Talicia(R) for Treatment of H. pylori in Adults

Subjects
United States. Food and Drug Administration -- Officials and employees, Tel-Aviv Stock Exchange Ltd. -- Officials and employees, Biological products industry -- Officials and employees, Rilpivirine, Rifabutin, Infection -- Drug therapy, Drug approval, Adults, Gastrointestinal diseases -- Drug therapy, Delavirdine, Amoxicillin, Helicobacter pylori, Metronidazole, Stock-exchange, Omeprazole, Securities industry -- Officials and employees, Securities industry, Banking, finance and accounting industries, Business, Aemcolo (Medication), Talicia (Medication)
Abstract

TEL-AVIV, Israel and RALEIGH, N.C., Nov 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:RDHL),(TASE:RDHL.TA), EQNX::TICKER_END RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ('RedHill' or the 'Company'), a [...]

Published
2019

49. Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

Subjects
United States. Food and Drug Administration, Antiparasitic agents, Cryptococcosis -- Drug therapy, Orphan drugs, Infection -- Drug therapy, Icosapent ethyl, Biological products industry, Amphotericin B, Antifungal agents, Technology, Drugs, Mycoses, Banking, finance and accounting industries, Business
Abstract

BEDMINSTER, N.J., Oct 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration [...]

Published
2019

50. GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

Subjects
Entasis Therapeutics Holdings Inc. -- Product development -- Research agreements, Clinical trials, Sulbactam -- Product development, Biotechnology industries -- Product development -- Research agreements, Medical research, Infection -- Drug therapy, Industrial research -- United States, Gonorrhea -- Drug therapy, Antibacterial agents -- Product development, Antibiotics, Sexually transmitted diseases, Drug resistance, Public health, Research and development, Banking, finance and accounting industries, Business, World Health Organization
Abstract

GENEVA and WALTHAM, Mass., Sep 30, 2019 (GLOBE NEWSWIRE via COMTEX) -- -- 87 million new gonorrhea infections estimated each year; Neisseria gonorrhoeae increasingly resistant to globally recommended treatments and [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results